ISSN: 2581-5989
PubMed - National Library of Medicine - ID: 101738774

International Journal of Dental Science and Innovative Research (IJDSIR)

IJDSIR : Dental Publication Service

Available Online at:www.ijdsir.com

Volume – 7, Issue – 5, September – 2024, Page No. : 137 - 142

Emerging Research and Therapies in Lichen Planus Management

[1]Dr. Sumit Bhatt, MDS, Senior Lecturer, Department of Oral and Maxillofacial Surgery, Rajasthan Dental College and Hospital, Jaipur, Rajasthan.

[2]Dr. Harini Patibandla, Tutor, NIMRA Institute of Dental Sciences, Ibrahimpatnam, Andhra Pradesh.

[3]Dr. Dhara Pankaj Ponda, Senior Oral and Maxillofacial Radiologist and Consultant, Mumbai.

[4]Dr. Tamoghna Jana, Senior Resident, Dept of Cleft and Craniofacial Surgery, Shree Jain Hospital and Research Center, Kolkata.

[5]Dr. Akhilesh Sankhyayan, MDS, Consultant Periodontist and Implantologist, Shimla, Himachal Pradesh.

[6]Dr. Satya Prakash, Reader, Department of Oral Medicine and Radiology, Patna, Bihar.

Corresponding Author: Dr. Sumit Bhatt, MDS, Senior Lecturer, Department of Oral and Maxillofacial Surgery, Rajasthan Dental College and Hospital, Jaipur, Rajasthan.

Citation of this Article: Dr. Sumit Bhatt, Dr. Harini Patibandla, Dr. Dhara Pankaj Ponda, Dr. Tamoghna Jana, Dr. Akhilesh Sankhyayan, Dr. Satya Prakash, "Emerging Research and Therapies in Lichen Planus Management", IJDSIR- September – 2024, Volume –7, Issue - 5, P. No. 137 – 142.

Type of Publication: Original Research Article

Conflicts of Interest: Nil

Abstract

Lichen planus (LP) is a chronic inflammatory dermatosis characterized by its diverse clinical presentations, affecting both the skin and mucous membranes. Its global prevalence, ranging from 0.22% to 5%, underscores its significance as a widespread dermatological concern. LP's multifactorial etiology, encompassing genetic, immune-mediated, and environmental factors, has made it a complex puzzle to decipher.

The clinical manifestations of LP encompass cutaneous, mucosal, and nail involvement, each presenting unique challenges and impacting patients' quality of life. Managing LP poses a formidable clinical challenge due to its chronic nature and variable course. The discomfort, psychological distress, and social stigma associated with LP further underscore the need for improved management strategies.

This review explores recent advancements in LP research and therapeutic strategies. It delves into the immunopathogenesis, clinical presentations, and current management approaches while emphasizing emerging research and innovative therapeutic avenues. By shedding light on these developments, this review aims to contribute to a better understanding of LP and pave the way for enhanced management strategies for individuals affected by this complex dermatological condition.

Keywords: Lichen Planus, Dermatosis, Immunopathogenesis, Microbiome.

Introduction

Lichen planus (LP) is a complex and enigmatic chronic inflammatory dermatosis that imposes a significant burden on affected individuals. It primarily targets the skin and mucous membranes, leading to a diverse range of clinical presentations. LP's worldwide prevalence, which varies between 0.22% to 5%, underscores its importance as a dermatological concern with a global impact. (1)

The quest to fully comprehend LP's etiology has spanned decades, and while significant progress has been made, it remains an intricate puzzle. The condition is believed to have a multifactorial origin, influenced by genetic predisposition, immune-mediated responses, and environmental factors. These intertwined elements contribute to the challenging nature of LP, as they complicate its pathogenesis and therapeutic management. (2,3)

Managing LP poses a formidable clinical challenge due to its diverse clinical manifestations and the variable course it may take. The condition can manifest in different forms, including cutaneous, mucosal, and even involving the nails. Each presentation brings its unique set of clinical challenges and impacts the patient's overall quality of life. The chronic nature of LP, coupled with its often debilitating effects, can result in physical discomfort, psychological distress, and social stigmatization. (4,5)

This review article aims to shed light on the latest advancements in LP research and therapeutic strategies. It delves into immunopathogenesis, clinical presentations, and current management approaches while focusing on emerging research and innovative therapeutic avenues. By exploring these developments, we hope to contribute to a better understanding of LP and pave the way for improved management strategies that enhance the lives of those affected by this complex dermatological condition.

Immunopathogenesis of Lichen Planus

In recent years, there has been significant progress in understanding the immunopathogenesis of lichen planus (LP). This knowledge is crucial for developing more effective and targeted therapies for this perplexing dermatological condition.

T-Cell-Mediated Immune Responses: One of the central findings in LP research is the role of T-cell-mediated immune responses. T cells, a type of white blood cell, are pivotal players in the body's immune system. In LP, there is evidence to suggest that certain subsets of T cells become activated and aberrantly respond to self-antigens, contributing to the development and progression of the disease. This immune dysregulation is thought to be a key driver of LP pathogenesis. (6,7)

Cytokines and Chemokines: The immunopathogenesis of LP involves a complex interplay of cytokines and chemokines. Cytokines are signaling molecules secreted by immune cells that regulate immune responses, while chemokines are responsible for attracting immune cells to sites of inflammation. Recent research has highlighted the involvement of specific cytokines and chemokines in LP. Notably, Th1 and Th17 cytokines, such as interferon-gamma (IFN-γ) and interleukin-17 (IL-17), are upregulated in LP lesions. These cytokines are associated with pro-inflammatory responses and are implicated in the recruitment and activation of immune cells in affected tissues. (8,9)

Tissue Inflammation and Keratinocyte Apoptosis: LP pathogenesis is characterized by tissue inflammation and the death of keratinocytes, the predominant cells in the epidermis (outer layer of skin). The infiltration of

inflammatory cells, including T cells and other immune cells, into the skin and mucous membranes contributes to the local inflammatory response. This inflammatory milieu, combined with the release of pro-inflammatory cytokines, leads to the apoptosis (programmed cell death) of keratinocytes. The loss of these skin cells further contributes to the clinical manifestations of LP, including characteristic skin lesions and mucosal erosions. (10)

Targeted Therapies: The insights gained from recent research into LP's immunopathogenesis hold promise for the development of more targeted therapies. By understanding the specific immune pathways and molecules involved, researchers can explore novel treatment options that aim to modulate the immune response in a more precise manner. For example, therapies that target Th1 and Th17 cytokines or inhibit the recruitment of inflammatory cells may offer new avenues for intervention. Janus kinase (JAK) inhibitors and biological agents that specifically target these pathways are currently being investigated and have shown promise in early clinical trials for LP management. (11)

Clinical Presentations of Lichen Planus

Lichen planus (LP) is a dermatological condition known for its diverse clinical presentations. Understanding these various manifestations is essential for accurate diagnosis and effective management. Recent research has shed light on the subtle differences in immune profiles and gene expression patterns associated with different forms of LP, offering potential avenues for tailored treatment approaches. (12)

Cutaneous LP: Cutaneous LP primarily affects the skin and is characterized by the presence of pruritic (itchy) flat-topped, violaceous (purple) papules and plaques. These skin lesions often have a polygonal shape and may be covered with fine white lines, a feature known as Wickham striae. Cutaneous LP can occur anywhere on the body but commonly affects the wrists, ankles, and lower back. Recent research has indicated that the immune mechanisms driving cutaneous LP may differ slightly from other forms of LP. For example, the specific immune cell populations and cytokines involved may vary, and this understanding could influence treatment choices. (13)

Oral LP: Oral LP affects the mucous membranes of the mouth and can be extremely uncomfortable, causing burning or painful sensations. It presents as white, lacy streaks or plaques on the mucous membranes, including the buccal mucosa, tongue, and gums. Recent studies have suggested that the immune response in oral LP may be distinct from cutaneous LP, and this insight is crucial for tailoring therapeutic strategies. Additionally, recognizing the potential for malignant transformation in some cases of oral LP highlights the importance of vigilant monitoring and early intervention. (14)

Nail Involvement: Nail involvement in LP is characterized by a range of abnormalities, including nail thinning, ridges, and pitting. Nail LP can cause pain and discomfort and may be challenging to treat. Research into the specific mechanisms behind nail LP is ongoing, but clinicians need to distinguish it from other nail conditions to provide appropriate care. (15)

Genital LP: LP can also affect the genital area, leading to erosions, white plaques, and discomfort. This variant of LP can be particularly distressing for patients and may require specialized management approaches. (16)

LP Variants: LP can present in various atypical or variant forms, such as hypertrophic LP, bullous LP, or actinic LP. These variants have distinct clinical and histological features, necessitating precise diagnosis and tailored treatments. Recent research has contributed to

the understanding of these variants, aiding clinicians in differentiating them from typical LP. (17)

The identification of subtle differences in the immune profiles and gene expression patterns associated with these different forms of LP holds promise for tailoring treatment approaches. Precision medicine, where therapies are matched to the specific immune mechanisms at play in each patient, may become more feasible as research in this area continues to evolve.

Current Treatment Approaches

Conventional treatment options for LP primarily focus on symptom relief and inflammation control. These include topical corticosteroids, calcineurin inhibitors, and systemic therapies such as oral corticosteroids or immunomodulatory agents like methotrexate and cyclosporine. However, these treatments often come with side effects and limited long-term efficacy.

Emerging Therapies

a. JAK Inhibitors: Janus kinase (JAK) inhibitors, such as tofacitinib and ruxolitinib, have shown promise in the treatment of LP by targeting the underlying immune dysregulation. Early clinical trials have demonstrated encouraging results, with rapid improvements in both cutaneous and oral LP lesions. (18)

b. Biologics: Biologic agents, including TNF-α inhibitors and IL-17 inhibitors, have shown potential in managing LP, particularly when conventional treatments fail. Their targeted action on specific immune pathways may provide a safer and more effective alternative for some patients. (19)

c. Phototherapy: Advances in phototherapy techniques, such as excimer laser and narrowband UVB, offer targeted treatment options for cutaneous LP. These approaches are less invasive and may reduce the side effects associated with systemic medications. (20)

d. Stem Cell Therapies: Emerging research explores the use of stem cell-based therapies to promote tissue regeneration and modulate the immune response in LP. These therapies hold promise in addressing the underlying pathology of LP rather than just managing symptoms. (21)

Future Directions: (21)

Future research in LP should continue to unravel its complex immunopathogenesis, with a focus on identifying biomarkers for disease activity and treatment response. Personalized medicine approaches may become more common, tailoring treatments to patients' specific immune profiles and clinical presentations.

Additionally, exploring the potential role of the microbiome in LP development and progression may lead to innovative therapeutic interventions. Furthermore, patient-reported outcomes and quality-of-life assessments should be integrated into clinical trials to better understand the impact of LP on individuals and evaluate treatment efficacy comprehensively.

Conclusion

Lichen planus remains a challenging dermatological condition to manage effectively. However, recent advancements in our understanding of its immunopathogenesis and the development of targeted therapies offer hope for improved treatment outcomes and quality of life for affected individuals. As research in LP continues to evolve, clinicians and researchers must stay updated on emerging therapies and approaches to optimize patient care.

References

1. Gorouhi F, Davari P, Fazel N. Cutaneous and Mucosal Lichen Planus: A Comprehensive Review of Clinical Subtypes, Risk Factors, Diagnosis, and Prognosis. Scientific World Journal.

2014;2014:742826. doi: 10.1155/2014/742826. PMCID: PMC3929580. PMID: 24672362.

2. Kumar V, Abbas A, Aster J. Robbins & Cotran Pathologic Basis of Disease. 8th ed edition. Philadelphia, Pa, USA: Saunders; 2009. [Google Scholar]
3. Daoud M, Pittelkow M. Lichen Planusin. In: Goldsmith L, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick's Dermatology in General Medicine. New York, NY, USA: McGraw-Hill; 2012. [Google Scholar]
4. De A, Rajagopalan M, Sarda A, Das S, Biswas P. Drug Reaction with Eosinophilia and Systemic Symptoms: An Update and Review of Recent Literature. Indian J Dermatol. 2018 Jan-Feb;63(1):30-40. doi: 10.4103/ijd.IJD_582_17. PMCID: PMC5838752. PMID: 29527023.
5. Goetz LH, Schork NJ. Personalized Medicine: Motivation, Challenges and Progress. Fertil Steril. 2018 Jun;109(6):952-963. doi: 10.1016/j.fertnstert.2018.05.006. PMCID: PMC6366451. PMID: 29935653.
6. Dobbs NA, Odeh AN, Sun X, Simecka JW. The multifaceted role of T cell-mediated immunity in pathogenesis and resistance to Mycoplasma respiratory disease. Curr Trends Immunol. 2009;10:1-19. PMCID: PMC3131222. PMID: 21743780.
7. Seiringer P, Garzorz-Stark N, Eyerich K. T-cell-mediated autoimmunity: Mechanisms and future directions. J Invest Dermatol. 2022 Mar;142(3 Pt B):804-810. doi: 10.1016/j.jid.2021.04.032.
8. Cameron MJ, Kelvin DJ. Cytokines, chemokines and their receptors. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; Available from: https://www.ncbi.nlm.nih.gov/books/NBK6271/
9. Ramesh G, MacLean AG, Philipp MT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm. 2013;2013:480739. doi: 10.1155/2013/480739. PMCID: PMC3753746. PMID: 23997430.
10. Anderton H, Alqudah S. Cell death in skin function, inflammation, and disease. Biochem J. 2022 Aug 12;479(15):1621-1651. doi: 10.1042/BCJ20210606. PMCID: PMC9444075. PMID: 35929827.
11. Weston G, Payette M. Update on lichen planus and its clinical variants. Int J Womens Dermatol. 2015 Aug;1(3):140-149. doi: 10.1016/j.ijwd.2015.04.001. PMCID: PMC5418875. PMID: 28491978.
12. Gorouhi F, Davari P, Fazel N. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. Sci World J. 2014;2014:742826. doi: 10.1155/2014/742826.
13. Mortazavi H, Safi Y, Baharvand M, Jafari S, Anbari F, Rahmani S. Oral white lesions: an updated clinical diagnostic decision tree. Dent J (Basel). 2019 Mar;7(1):15. doi: 10.3390/dj7010015. PMCID: PMC6473409. PMID: 30736423.
14. Wechsuruk P, Bunyaratavej S, Kiratiwongwan R, Suphatsathienkul P, Wongdama S, Leeyaphan C. Clinical features and treatment outcomes of nail lichen planus: A retrospective study. JAAD Case Rep. 2021 Nov;17:43-48. doi: 10.1016/j.jdcr.2021.09.015. PMCID: PMC8526913. PMID: 34703863.
15. Khurana A, Tandon S, Marfatia YS, Madnani N. Genital lichen planus: An underrecognized entity. Indian J Sex Transm Dis AIDS. 2019 Jul-

Dec;40(2):105-112. doi: 10.4103/ijstd.IJSTD_45_19. PMCID: PMC6896385. PMID: 31922099.

16. Weston G, Payette M. Update on lichen planus and its clinical variants. Int J Womens Dermatol. 2015 Sep 16;1(3):140-149. doi: 10.1016/j.ijwd.2015.04.001. PMID: 28491978; PMCID: PMC5418875.
17. Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017 Apr;76(4):736-744. doi: 10.1016/j.jaad.2016.12.005. PMCID: PMC6035868. PMID: 28139263.
18. Țiburcă L, Bembea M, Zaha DC, Jurca AD, Vesa CM, Rațiu IA, Jurca CM. The treatment with interleukin 17 inhibitors and immune-mediated inflammatory diseases. Curr Issues Mol Biol. 2022 May;44(5):1851-1866. doi: 10.3390/cimb44050127. PMCID: PMC9164043. PMID: 35678656.
19. Barros NdeM, Sbroglio LL, Buffara MO, Baka JLCeS, Pessoa AdS, Azulay-Abulafia L. Phototherapy. An Bras Dermatol. 2021 Jul-Aug;96(4):397-407. doi: 10.1016/j.abd.2021.03.001. PMCID: PMC8245715. PMID: 33849754.
20. Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, Nguyen GH, Le PTT, Hoang VT, Forsyth NR, Heke M, Nguyen LT. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022;7:272. doi: 10.1038/s41392-022-01134-4. PMCID: PMC9357075. PMID: 35933430.
21. Vanden Berghe T, Hoste E. Paving the way for precision medicine v2.0 in intensive care by profiling necroinflammation in biofluids. Cell Death Differ. 2019;26:83-98. doi: 10.1038/s41418-018-0197-3.